The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.u Pneumoconiosis (silicosis, talcosis...)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.ae Cough syncope

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.i Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aj Nasal, palatal and/or pharyngeal pathology

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.r Empyema

VI. Pleural and/or pericardial involvement

VI.ac Pneumothorax, bilateral

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VII. Pulmonary vasculopathy

VII.c Pulmonary veno-occlusive disease

VII. Pulmonary vasculopathy

VII.g Foreign body pulmonary vasculopathy (Excipient lung disease)

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

VII. Pulmonary vasculopathy

VII.j Mercury pulmonary embolism

VII. Pulmonary vasculopathy

VII.q Septic pulmonary embolism

VII. Pulmonary vasculopathy

VII.r Pulmonary artery aneurysm(s)

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

VIII. Mediastinal involvement

VIII.i Mediastinitis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.s Botulism (foodborne-, wound-)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ah Acute myelopathy (can cause ARF)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.bc Foreign body (talc, cornstarch) retinopathy

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.h Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

XI. Miscellaneous

XI.k Pulmonary emphysema - Lung cysts or bullae

XI. Miscellaneous

XI.o Death following exposure or poisoning

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.j Endocarditis (infective)

XII. Cardiovascular involvement / toxicity

XII.x Hypertrophic cardiomyopathy

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XVI. Imaging

XVI.u Imaging: A miliary pattern (diffuse random micronodules)

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.ag Imaging: A pattern similar to pneumoconiotic progressive massive fibrosis (PMF)

XVI. Imaging

XVI.ak Imaging: A 'tree-in-bud' pattern

XVII. Distinctive patterns - 'Eye-catchers'

XVII.t Eye catcher: Purpuric/Ecchymotic/Cyanotic lesions of the earlobes and/or nose

XVII. Distinctive patterns - 'Eye-catchers'

XVII.u Eye catcher: Talc retinopathy

XVII. Distinctive patterns - 'Eye-catchers'

XVII.x Eye catcher: A batwing pattern on imaging

XIX. Pathology

XIX.j Path: Micronodular organizing pneumonia/BOOP

XIX. Pathology

XIX.ab Path: Foreign body deposits/granulomatous reaction

XIX. Pathology

XIX.ac Path: Pneumoconiosis (silicosis, talcosis, talcoma)

XIX. Pathology

XIX.an Path: Foreign body embolism, microangiopathy, vasculopathy

XIX. Pathology

XIX.ax Path: Pulmonary hypertension incl. angiomatoid vasculopathy

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.p Lung abscess/abscesses (see also VIr)

XX. Infections & related conditions

XX.s Sternoclavicular septic arthritis

XX. Infections & related conditions

XX.t Epidural abscess

XX. Infections & related conditions

XX.ak Osteomyelitis (notably of thoracic bones)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

I. Interstitial/parenchymal lung disease

I.au Amiodarone pulmonary toxicity - Amiodarone lung

I. Interstitial/parenchymal lung disease

I.ay Chronic pneumonitis

I. Interstitial/parenchymal lung disease

I.az Unilateral interstitial lung disease

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.m Postoperative ARDS

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.k Airway pigmentation (black, bluish, petechial)

IV. Airway involvement

IV.ab Cough (lone)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.c Pleural thickening - Fibrothorax

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.u The apical cap

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ai Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.s Systemic inflammatory response

XI. Miscellaneous

XI.c Pleuritic chest pain

XI. Miscellaneous

XI.g Bluish, pseudocyanotic skin discoloration

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.q QTc prolongation

XII. Cardiovascular involvement / toxicity

XII.v Torsades de pointe

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.aw Heart failure (thyrotoxicosis-, thyroid storm-mediated)

XV. Pulmonary physiology - PFTs

XV.g Platypnea-orthodeoxia

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.j Imaging: Wandering (migratory) pulmonary opacities

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.x Imaging: Waxing and waning nodules

XVI. Imaging

XVI.ab Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ba Imaging: Asymmetrical, predominantly unilateral involvement

XVI. Imaging

XVI.bb Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

XVI. Imaging

XVI.bt Imaging: A pattern consistent with pleuroparenchymal fibroelastosis

XVI. Imaging

XVI.bv Imaging: A subsolid lung nodule or nodules

XVI. Imaging

XVI.cb Imaging: Disseminated patchy pulmonary opacities

XVII. Distinctive patterns - 'Eye-catchers'

XVII.b Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.j Eye-catcher: Avid lung uptake on 18F-PET-CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.k Eye-catcher: An electron-dense liver on unenhanced CT

XVII. Distinctive patterns - 'Eye-catchers'

XVII.p Eye-catcher: An electron-dense ('white') thyroid

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.e BAL: Stainable iron in macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.f BAL: Foamy macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.m BAL: A normal cell differential

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.p BAL: Lamellar bodies in AM on EM

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.c Path: Acute eosinophilic pneumonia pattern (see also under XVIb)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.k Path: Desquamative interstitial pneumonia (DIP-pattern)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.w Path: Pulmonary fibrosis (UIP-pattern)

XIX. Pathology

XIX.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

XIX. Pathology

XIX.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XIX. Pathology

XIX.ag Path: Histiocytic proliferation

XIX. Pathology

XIX.aj Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

XIX. Pathology

XIX.ak Path: Smudged geographic necrosis

XIX. Pathology

XIX.bm Path: Pleuritis, pleural fibrosis

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.g Transfusion-related acute lung injury (TRALI) (May cause ARDS)

II. Pulmonary edema - Acute lung injury - ARDS

II.h Hypoxemia, low oxygen saturation (may occur in isolation)

II. Pulmonary edema - Acute lung injury - ARDS

II.j Overload pulmonary edema (including posttransfusional (TACO))

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

VII. Pulmonary vasculopathy

VII.n Crystal pulmonary embolism

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.e Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XII. Cardiovascular involvement / toxicity

XII.k Myocardial stunning

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.t Path: Pulmonary edema (see also II/IIa)

XIX. Pathology

XIX.bj Path: Cholesterol crystal embolism

XIX. Pathology

XIX.bl Path: Pulmonary capillary granulocyte sequestration

XX. Infections & related conditions

XX.ac Systemic infection (transmitted)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

VII. Pulmonary vasculopathy

VII.t Foreign body/substance pulmonary embolism

XI. Miscellaneous

XI.x CNS symptoms or involvement, stroke

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XIX. Pathology

XIX.an Path: Foreign body embolism, microangiopathy, vasculopathy

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

XI. Miscellaneous

XI.at Chest tightness

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.ak Cardiotoxicity

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

VII. Pulmonary vasculopathy

VII.p Rebound pulmonary arterial hypertension